<i>Helicobacter pylori</i> eradication treatment and the risk of gastric adenocarcinoma in a Western population

Doorakkers, Eva; Lagergren, Jesper; Engstrand, Lars; Brusselaers, Nele

doi:10.1136/gutjnl-2017-315363

Cited by 106 publications

(81 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…79 Recently, incremental data has demonstrated that eradication treatment for H. pylori could reduce the risk of gastric cancer. 80,81 Collectively, these studies indicate that gastric microbiota is involved in gastric carcinogenesis. With enormous microorganism at close proximity to the colonic epithelial cells, the involvement of gut microbiota in colorectal carcinogenesis is becoming clear.…”

Section: Fmt For Digestive System Cancersmentioning

confidence: 81%

“…Significant enrichment of Peptostreptococcus stomatis , Parvimonas micra , Streptococcus anginosus , Dialister pneumosintes , Slackia exigua, Clostridium colicanis and Fn and depletion of Helicobacterium was observed in gastric cancer, and alterations in bacterial diversity and abundance in patients with gastric cancer revealed a dysbiotic microbial community with prediction potential . Recently, incremental data has demonstrated that eradication treatment for H. pylori could reduce the risk of gastric cancer . Collectively, these studies indicate that gastric microbiota is involved in gastric carcinogenesis.With enormous microorganism at close proximity to the colonic epithelial cells, the involvement of gut microbiota in colorectal carcinogenesis is becoming clear.…”

Section: Fmt As a Possible Therapy For Various Type Of Cancers And Camentioning

confidence: 91%

See 1 more Smart Citation

Fecal microbiota transplantation in cancer management: Current status and perspectives

Chen

Jin

et al. 2018

Intl Journal of Cancer

239

161

View full text Add to dashboard Cite

The human gut is home to a large and diverse microbial community, comprising about 1,000 bacterial species. The gut microbiota exists in a symbiotic relationship with its host, playing a decisive role in the host's nutrition, immunity and metabolism. Accumulating studies have revealed the associations between gut dysbiosis or some special bacteria and various cancers. Emerging data suggest that gut microbiota can modulate the effectiveness of cancer therapies, especially immunotherapy. Manipulating the microbial populations with therapeutic intent has become a hot topic of cancer research, and the most dramatic manipulation of gut microbiota refers to fecal microbiota transplantation (FMT) from healthy individuals to patients. FMT has demonstrated remarkable clinical efficacy against Clostridium difficile infection (CDI) and it is highly recommended for the treatment of recurrent or refractory CDI. Lately, interest is growing in the therapeutic potential of FMT for other diseases, including cancers. We briefly reviewed the current researches about gut microbiota and its link to cancer, and then summarized the recent preclinical and clinical evidence to indicate the potential of FMT in cancer management as well as cancer‐treatment associated complications. We also presented the rationale of FMT for cancer management such as reconstruction of intestinal microbiota, amelioration of bile acid metabolism, and modulation of immunotherapy efficacy. This article would help to better understand this new therapeutic approach for cancer patients by targeting gut microbiota.

show abstract

Section: Fmt For Digestive System Cancersmentioning

confidence: 81%

Section: Fmt As a Possible Therapy For Various Type Of Cancers And Camentioning

confidence: 91%

Fecal microbiota transplantation in cancer management: Current status and perspectives

Chen

Jin

et al. 2018

Intl Journal of Cancer

239

161

View full text Add to dashboard Cite

show abstract

“…According to Suzuki et al [31], H. pylori infection can produce pathological changes similar to LGIN, and after eradication of H. pylori infection, the pathological manifestations of atypical hyperplasia can be improved or even reversed with subsidence of active gastritis. Doorakkers et al [32] reported that the risk of gastric adenocarcinoma decreased over time after eradication treatment, to levels below that of the corresponding background population. This suggests that it is important to treat H. pylori as early as possible.…”

Section: Discussionmentioning

confidence: 99%

Analysis of Risk Factors of Gastric Low-Grade Intraepithelial Neoplasia in Asymptomatic Subjects Undergoing Physical Examination

Liu

Cai

Chen

et al. 2020

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Secondary prevention is an important strategy in gastric cancer. Low-grade intraepithelial neoplasia (LGIN) is the last stage of precancerous lesion, and its timely diagnosis can greatly improve the detection rate of early gastric cancer. We performed a prospective study to analyze the risk factors of gastric LGIN in asymptomatic subjects undergoing physical examination. A total of 3437 subjects were included in this study, and 2259 asymptomatic subjects were investigated from March 2015 to April 2018. Risk factors were evaluated, and the endoscopic features of LGIN and prognosis were described. The overall incidence of LGIN was 19.73% (678/3437), while the incidence of LGIN in the asymptomatic and symptomatic groups was 19.65% (444/2259) and 19.86% (234/1178), respectively (P = 0:884). The rate of Helicobacter pylori infection in this physical examination population was 39.13% (35.8% asymptomatic group, 45.5% symptomatic group; P ≤ 0:001). Risk factors including age, H. pylori infection, history of antibiotic misuse, and spicy and high-fat diet (all P < 0:05) were further verified by multivariate analysis as independent risk factors. History of antibiotic misuse and H. pylori infection showed significant associations with LGIN (odds ratio ðORÞ = 6:767, 95% confidence interval (CI) 3.873-11.825 and OR = 3:803, 95% CI 3.009-4.808, respectively). The most common endoscopic classification of LGIN was erosive gastritis (50.78%), and the major endoscopic appearance was Paris IIa (flat with slight elevation located mostly in the antrum). During the mean follow-up period of 15.02 months, 49.4% of LGIN regressed, 0.61% of LGIN progressed, and 50% of LGIN remained unchanged. History of antibiotic misuse and H. pylori infection were predominant risk factors of LGIN in asymptomatic subjects, and those individuals should consider early screening for gastric cancer.

show abstract

“…Moreover, long‐term H pylori infection can lead to gastric malignancies, which have been demonstrated in both human and animal models; thus, H pylori has been recognized as a class I carcinogen by the International Agency for Research on Cancer . Recently, a number of clinical studies have demonstrated that the earlier H pylori eradication therapy is given, especially prior to the development of precancerous lesions, the more effective it will be in reducing the risk of gastric cancer . Therefore, nationwide eradication therapy has been implemented in some countries, such as Japan and Korea, which is considered the primary prevention method for gastric cancer …”

Section: Introductionmentioning

confidence: 99%

“…2 Recently, a number of clinical studies have demonstrated that the earlier H pylori eradication therapy is given, especially prior to the development of precancerous lesions, the more effective it will be in reducing the risk of gastric cancer. [3][4][5] Therefore, nationwide eradication therapy has been implemented in some countries, such as Japan and Korea, which is considered the primary prevention method for gastric cancer. 6,7 With the increase in antibiotic resistance, the clarithromycin-or metronidazole-based standard triple therapy for H pylori infection is no longer recommended in China because of its low efficacy.…”

Section: Introductionmentioning

confidence: 99%

The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults

et al. 2019

View full text Add to dashboard Cite

Background The eradication of Helicobacter pylori (H pylori) has been suggested to reduce the risk of gastric cancer, but its impact on the gut microbiota has attracted public attention. This study aimed to investigate the short‐term and long‐term effects of bismuth quadruple therapy on both gastric and fecal microbiota. Methods Ten asymptomatic young adults with H pylori‐related gastritis were treated with bismuth quadruple therapy for 14 days, and 7 age‐matched adults without H pylori infection were enrolled as healthy controls. Both fecal and gastric mucosa samples were collected from H pylori‐positive patients at weeks 0, 6, and 26, while fecal samples were collected from healthy controls. The gastric and gut microbiota were analyzed by 16S rRNA gene sequencing. Results The structure of the gastric microbiota was significantly changed after the eradication of H pylori with increased alpha diversity over time. The relative abundance of H pylori sharply decreased from more than 70% to nearly 0% after treatment, while some beneficial bacteria, such as Lactobacillus and Bifidobacterium, were increased. The microbial diversity of gut microbiota was higher in H pylori‐infected patients than in healthy controls, which tended to decrease after eradication. The potentially beneficial gut bacteria Blautia and Lachnoclostridium were enriched at week 26 compared to week 0, while the pathogenic Alistipes were depleted to a level close to that of the healthy controls. Conclusions Bismuth quadruple therapy for H pylori eradication can restore the diversity of gastric microbiota with enrichment of beneficial bacteria. The composition of gut microbiota after H pylori eradication trends toward healthy status instead of becoming dysbiotic.

show abstract

Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population

Abstract: Eradication treatment for seems to counteract the development of gastric adenocarcinoma and non-cardia gastric adenocarcinoma in this Western population.

Cited by 106 publications

References 18 publications

Fecal microbiota transplantation in cancer management: Current status and perspectives

Fecal microbiota transplantation in cancer management: Current status and perspectives

Analysis of Risk Factors of Gastric Low-Grade Intraepithelial Neoplasia in Asymptomatic Subjects Undergoing Physical Examination

The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults

Contact Info

Product

Resources

About